To improve the effectiveness of spinal cord stimulation for pain management, Boston Scientific is now making available the Precision Spectra in Europe.
The newly CE marked device is the first spinal cord stimulator featuring 32 contacts, each driven by a dedicated power source.
From the announcement:
Until now, SCS systems have offered a maximum of 16 contacts and two lead ports, with each lead port allowing the placement of one lead. By providing 32 contacts and four lead ports—twice that of any other SCS system—the Precision Spectra System offers more coverage of the spinal cord for the management of chronic pain. Additional lead ports also give physicians more flexibility to treat their patients’ pain at time of implant and more flexibility to adapt to changing pain patterns in the future.
“Over the past 30 years, SCS systems have evolved from four to eight to 16 contacts. At each step, we have seen an improvement in our ability to cover pain,” said Dr. Thomson. “Now, by doubling the number of contacts to 32 while providing a dedicated power source for each contact, the Precision Spectra System advances our ability to provide pain relief.”
The Precision Spectra SCS System is currently under review by the U.S. Food and Drug Administration, and is not available for sale in the United States.
Press release: Boston Scientific Receives European Regulatory Approval For New Precision Spectra™ Spinal Cord Stimulator System